Cancer Diagnostics Dealmaking in Biopharma Investigated in New CurrentPartnering Report Available at MarketPublishers.com13 May 2014 • by Natalie Aster
LONDON – The majority of the cancer diagnostics deals are discovery and/or development stage whereby the licensee receives an option or a right to license the licensors cancer diagnostics technology. The cancer diagnostics partnering deals tend to be multicomponent, beginning from collaborative research and development, and commercialisation of results. Abbott, Eisai, Merck KGaA, Bristol-Myers Squibb, AstraZeneca, Gilead Sciences, Gilead Sciences, Amgen, Johnson & Johnson, Novartis, Bayer, Roche, Astellas and Celgene are among the dominant healthcare companies that enter into the cancer diagnostics partnering deals.
A clear understanding of a prospective partner’s flexibility in negotiated deals terms provides critical insights into the partnership negotiation process regarding the outcomes expected to be achieved during the negotiation of terms.
New research study “Cancer Diagnostics Partnering Terms and Agreements” worked out by CurrentPartnering presents a clear understanding of the cancer diagnostics partnering terms and agreements, besides providing access to the cancer diagnostics partnering deals and agreements entered into by the world’s top healthcare companies.
A comprehensive summary of the prevailing trends in cancer diagnostics partnering deals; a complete set of contract documents; ranking of the cancer diagnostics deals by value and top-level data on upfronts, headlines, royalties and milestones by stage of development are provided in the cutting-edge research study. The insightful report discusses why and how the dominant healthcare companies enter cancer diagnostics partnering deals, and also includes above 900 links to online copies of present cancer diagnostics deals. Besides, the cutting-edge report gives answers to a range of questions concerning a prospective partner’s flexibility on a slew of important issues.
Cancer Diagnostics Partnering Terms and Agreements
Published: May, 2014
Price: US$ 2,995.00
Other Healthcare Partnering Terms & Agreements Reports by CurrentPartnering:
- Gene Therapy Partnering Terms and Agreements
- Cancer Vaccine Partnering Terms and Agreements
- Hematology Partnering Terms and Agreements
- Companion Diagnostics Partnering Terms & Agreements
- Asset Purchase Terms and Agreements in Pharma, Biotech and Diagnostics
- Genitourinary Partnering Terms and Agreements
- Personalized Medicine Partnering Terms and Agreements
More new research studies by the publisher can be found at CurrentPartnering page.